3. Austin MA, King MC, Vranizan KM et al.: Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506. [PubMed]
5. Puri V, Ranjit S, Konda S et al: Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc Natl Acad Sci 2008; 105: 7833-38.
6. Norgren L, Hiatt WR , Dormandy JA et al.: Intersociety consensus for the management of peripherial arterial disease. Int Angiol 2007; 26: 81-157.
7. Chomczyński P, Sacchi N: Single-step metod of RNA isolation by acid guanidinum thiocyanate phenol-chloroform extraction. Anal Biochem 1987; 162: 156-59. [Crossref]
8. Zhou Z, Yon Toh S, Chen Z et al.: Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat Genet 2003; 35: 49-56.
9. Zespół metaboliczny - nowa definicja i zasady leczenia. Aktualne (2005) stanowisko International Diabetes Federation. Medycyna Praktyczna 2005; 5: 45-55.
10. Mattiason I, Rendell M, Tornquist C et al.: Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. Hormone Metab Res 2002; 34: 583-88.
11. Wade GN , Gray JM: Gonadal effects on food intake and adiposity: a metabolic hypothesis. Physiol Behav 1979; 22: 583-93. [PubMed]
12. Siemińska L: Tkanka tłuszczowa. Patofizjologia, rozmieszczenie, różnice płciowe oraz znaczenie w procesach zapalnych i nowotworowych. Pol J Endocrinol 2007; 58: 330-42.
13. Viguerie N, Vidal H, Arner P et al.: Nutrient- Gene Interactions in Human Obesity - Implications for Dietary Guideline (NUGENOB) project: Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetol 2005; 48: 123-31.
14. Gummesson A, Jernas M, Svensson PA et al.: Relations of adipose tissue CIDEA gene expression to basal metabolic rate, energy restriction, and obesity: population-based and dietary intervention studies. J Clin Endocrinol Metab 2007; 92: 4759-65. [PubMed] [Web of Science]
15. Nordstrom EA , Ryden M, Backlund EC et al.: A human-specific role of cell death-inducing DFF A (DNA fragmentation factor-alpha)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 2005; 54: 1726-34.
16. Cnop M, Landchild MJ, Vidal J et al.: The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002; 51: 1005-15.
17. Ferrara CM, Lynch NA , Nicklas BJ et al: Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab 2002; 87: 4166-70. [PubMed]
18. Xu L, Zhou L, Li P: Cide proteins and lipid metabolism. Thrombosis and Vascular Biology 2012; 32: 1094-98.
Polish Journal of Surgery
The Journal of Foundation of the Polish Journal of Surgery
SCImago Journal Rank (SJR) 2015: 0.214
Source Normalized Impact per Paper (SNIP) 2015: 0.336
Impact per Publication (IPP) 2015: 0.443
CIDE-A gene expression in patients with abdominal obesity and LDL hyperlipoproteinemia qualified for surgical revascularization in chronic limb ischemia
1Department of Vascular Surgery and Angiology, Medical University in Lublin
2Department of Clinical Genetics, Medical University in Lublin
3Department of Cardiology, Medical University in Lublin
4Department of Pedeutology and Health Education, Maria Skłodowska-Curie University in Lublin
5Department of Psychiatry, Neuropsychiatric District Hospital in Lublin
This content is open access.
Citation Information: Polish Journal of Surgery. Volume 85, Issue 11, Pages 644–648, ISSN (Print) 0032-373X, DOI: https://doi.org/10.2478/pjs-2013-0097, December 2013
- Published Online:
According to the latest data, CIDE -A gene plays a key role in the regulation of body weight in both humans and mice, and therefore it is regarded a potential candidate gene for human obesity.
The aim of the study was to define the role of CIDEA gene in patients with dyslipidemia and symptomatic limb ischemia.
Material and methods. The study group contained 28 patients, including 17 men and 11 women. Patients were enrolled in the study group, depending on the value of body mass index (BMI); there was BMI>30 for obese patients. The group included untreated patients (n=14) and patients (n=14) receiving atorvastatin 20 mg/day for at least three months prior to the initiation of the study. The control group (n=16) contained patients with no lipid disorders. A one-step isolation of RNA from lymphocytes and adipose tissue cells was carried out using the TRI method modified by Chomczyński and Sacchi. Next, gene expression was tested using real-time PCR.
Results. The highest mean relative expression of CIDE -A gene occurred in patients with normal body weight. The lowest mean relative expression of CIDE-A gene was observed in obese patients with lipid disorders. A high negative correlation (r=-0.7919) of CIDE -A gene expression, depending on BMI, was reported in the group of obese patients with lipid disorders.
Conclusions. Due to an important role of Cide-A protein demonstrated in the development of metabolic diseases such as obesity, metabolic syndrome, type 2 diabetes and their vascular complications, CIDE -A gene and protein are potential therapeutic targets in the case of these diseases.